Invasion assays
The ability of MMP-9 expression and activity to impact the invasiveness of parental (i.e., empty vector) and CST-Abl-expressing 4T1 cells was determined by measuring their invasion through Matrigel-coated (diluted 1:25 in serum-free medium; BD Biosciences) modified Boyden chambers as described [2] .
MMP-9 tumor studies
4T1 cells engineered to express either empty vector (i.e., Scram), shRNA against MMP-9 (i.e., shMMP-9), autoactivating G100L-MMP-9 (i.e., CaMMP9), CST-Abl, or CST-Abl in combination with CaMMP9 were engrafted into the 4th inguinal mammary fat pad (10,000 cells/ injection) of syngeneic 6-8 week old female Balb/C mice (Jackson Laboratories). Primary 4T1 tumor growth was monitored over a span of 28 days as described [2] . All animal studies were performed according to animal protocol procedures approved by the Institutional Animal Care and Use Committee of the University of Colorado.
UHCMC TMA immunohistochemical analyses
Deidentified human breast tissue microarrays were obtained through University Hospitals Case Medical Center (UHCMC)/Case Comprehensive Cancer Center (CCCC) and were previously processed and evaluated for ER, PR, and HER2 expression (IRB Protocol 01-13-43C and CASE 7114). A total of 157 tumor samples were evaluated and represented the following receptordefined subtypes: ER + /PR + /HER2 -(n = 49), ER -/PR -/HER2 + (n = 29), ER + /PR + /HER2+ (n = 20), ER -/PR -/HER2 -(n = 47), and other patients (n = 12). Additional clinicopathologic characteristics are described elsewhere [4] . Immunohistochemical (IHC) staining of c-Abl and p53 in formalin-fixed paraffin-embedded normal and tumor tissues was performed using anti-c-Abl antibody (Abcam Inc. Cat. # ab15130) and the CONFIRM p53 clone D0-7 (Ventana Medical Systems Inc. Cat. #790-2912), respectively. Slides were baked at 60°C, dewaxed, and rehydrated. Epitopes were retrieved by heating the slides for 20 min using either the Bond Epitope Retrieval 1 for c-Abl (citrate-based solution, pH 6.0; Leica Biosystems) or Cell Conditioning 1 for p53 (ethylenediaminetetraacetic acid-based solution, pH 9.0, Ventana Medical Systems Inc.), at which point all slides were treated for an additional 5 min treatment with 3% hydrogen peroxide to inactivate endogenous peroxidase. Afterward, the slides were incubated with either the anti-c-Abl rabbit polyclonal antibody (2 μg/mL) or anti-p53 antibody (ready-to-use reagent) for 15 min, and subsequently were developed using a polymer based detection system and counterstained with hematoxylin. All tissue slides were evaluated and scored by a board-certified pathologist. c-Abl immunostaining was quantified by signal intensity on a 3+ scale, where samples were placed into low (1) and high (2-3+) groups to facilitate statistical analyses. Positive p53 staining was indicative of breast cancers that expressed mutant p53. Statistical comparisons analyzing the probability of patient survival outcomes between groups were performed using the log-rank test. Figure S1 : Differential requirement for MMP-9 activity in regulating 4T1 cell proliferation and invasion. (A and B) 4T1 cell derivatives were incubated in the absence or presence of TGF-β1 (5 ng/ml) for 24 h. Afterwards, alterations in MMP-9 expression was measured by immunoblotting (A), while differences in MMP-9 activity was assessed by fluorimetric assays (B). 
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